Podcasts about Exact sciences

In this episode, David Harding, Senior Vice President of Pipeline Product Management at Exact Sciences, discusses a new survey of healthcare executives on multi-cancer early detection. He shares insights on system readiness, patient demand, and the barriers health systems face in adopting this transformative approach to cancer screening.This episode is sponsored by Exact Sciences.

David Harding, senior vice president, pipeline product management at Exact Sciences, joins HealthLeaders for a discussion on how to help health system leaders understand the foundation of Multi-Cancer Early Detection (MCED) and how it can impact cancer diagnosis, drive innovation and improve patient outcomes. Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice.

Dr. Hope Rugo and Dr. Giuseppe Curigliano discuss recent developments in the field of bispecific antibodies for hematologic and solid tumors, including strategies to optimize the design and delivery of the immunotherapy. TRANSCRIPT Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center. I am also the editor-in-chief of the Educational Book. Bispecific antibodies represent an innovative and advanced therapeutic platform in hematologic and solid tumors. And today, I am delighted to be joined by Dr. Giuseppe Curigliano to discuss the current landscape of bispecific antibodies and their potential to reshape the future of precision oncology. Dr. Curigliano was the last author of an ASCO Educational Book piece for 2025 titled, "Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances." Dr. Curigliano is a breast medical oncologist and the director of the Early Drug Development Division and chair of the Experimental Therapeutics Program at the European Institute of Oncology in Milan. He is also a full professor of medical oncology at the University of Milan. You can find our disclosures in the transcript of this episode. Dr. Curigliano, Giuseppe, welcome and thanks for being here. Dr. Giuseppe Curigliano: Thanks a lot for the invitation. Dr. Hope Rugo: Giuseppe, I would like to first ask you to provide some context for our listeners on how these novel therapeutics work. And then perhaps you could tell us about recent developments in the field of bispecific antibodies for oncology. We are at a time when antibody-drug conjugates (ADCs) are all the rage and, trying to improve on the targeting of specific antigens, proteins, receptors in the field of oncology is certainly a hot and emerging topic. Dr. Giuseppe Curigliano: So, thanks a lot. I believe really it was very challenging to try to summarize all the bispecific antibodies that are under development in multiple solid tumors. So, the first thing that I would like to highlight is the context and the mechanism of action of bispecific antibodies. Bispecific antibodies represent a groundbreaking advancement in cancer immunotherapy, because these engineered molecules have the unique ability to target and simultaneously bind to two distinct antigens. That is why we call them bispecific. So typically, one antigen is expressed on the tumor cell and the other one is expressed on the immune effectors, like T-cell or natural killer cells. So this dual targeting mechanism offers several key advantages over conventional monoclonal antibodies because you can target at the same time the tumor antigen, downregulating the pathway of proliferation, and you can activate the immune system. So the primary mechanism through which bispecific antibodies exert their therapeutic effects are: First, T-cell redirecting. I mean, many bispecific antibodies are designed to engage tumor-associated antigens like epidermal growth factor receptor, HER2, on the cancer cell and a costimulatory molecule on the surface of T-cell. A typical target antigen on T-cell is CD3. So what does it mean? That you activate the immune system, immune cells will reach the tumor bed, and you have a dual effect. One is downregulating cell proliferation, the other one is activation of the immune system. This is really important in hematological malignancies, where we have a lot of bispecifics already approved, like acute lymphoblastic leukemia or non-Hodgkin lymphoma.  The second, in fact, is the engagement of the tumor microenvironment. So, if you engage immune effector cells like NK cells or macrophages, usually the bispecific antibodies can exploit the immune system's ability to recognize and kill the immune cells, even if there is a lack of optimal antigen presentation.  And finally, the last mechanism of action, this may have a role in the future, maybe in the early cancer setting, is overcoming immune evasion. So bispecific antibodies can overcome some of the immune evasion mechanisms that we see in cancer. For example, bispecific antibodies can target immune checkpoint receptors, like PD-L1 and CTLA-4. Actually, there is a bispecific under development in breast cancer that has a dual targeting on vascular endothelial growth factor receptor and on PD-L1. So you have a dual effect at the same time. So, what is really important, as a comment, is we need to focus first on the optimal format of the bispecific, the optimal half-life, the stability, because of course even if they are very efficient in inducing a response, they may give also a lot of toxicities. So in clinical trials already, we have several bispecifics approved. In solid tumors, very few, specifically amivantamab for non-small cell lung cancer, but we have a pipeline of almost 40 to 50 bispecifics under development in multiple solid tumors, and some of them are in the context of prospective randomized trials. Dr. Hope Rugo: So this is really a fascinating area and it's really exciting to see the expansion of the different targets for bispecific antibodies. One area that has intrigued me also is that some of the bispecifics actually will target different parts of the same receptor or the same protein, but presumably those will be used as a different strategy. It's interesting because we have seen that, for example, in targeting HER2. Dr. Giuseppe Curigliano: Oh, yes, of course. You may consider some bispecifics like margetuximab, I suppose, in which you can target specifically two different epitopes of the same antigen. This is really an example of how a bispecific can potentially be more active and downregulating, let us say, a pathway, by targeting two different domains of a specific target antigen. This is an important point.  Of course, not all the bispecifics work this way, because some of the target antigen may dimerize, and so you have a family of target antigen; an example is epidermal growth factor receptor, in which you have HER1, HER2, HER3, and HER4. So some of them can inhibit the dimerization between one target antigen and the other one, in order to exert a more antiproliferative effect. But to be honest, the new generation of them are more targeting two different antigens, one on the tumor and one on the microenvironment, because according to the clinical data, this is a more efficient way to reduce proliferation and to activate the immune system. Dr. Hope Rugo: Really interesting, and I think it brings us to the next topic, which is really where bispecific antibodies have already shown success, and that is in hematologic malignancies where we have seen very interesting efficacy and these are being used in the clinic already. But the expansion of bispecific antibodies into solid tumors faces some key challenges. It's interesting because the challenges come in different shapes and forms. Tell us about some of those challenges and strategies to optimize bispecific antibody design, delivery, patient selection, and how we are going to use these agents in the right kind of clinical trials. Dr. Giuseppe Curigliano: This is really an excellent question because despite bispecific antibodies having shown a remarkable efficacy in hematological malignancies, their application in solid tumors may have some challenges. The first one is tumor heterogeneity. In hematological malignancy, you have a clear oncogene addiction. Let us say that 90% of the cells may express the same antigen. In solid tumors, it is not the same. Tumor heterogeneity is a typical characteristic of solid tumors, and you have high heterogeneity at the genetic, molecular, and phenotypic levels. So tumor cells can differ significantly from one another, even if within the same tumor. And this heterogeneity sometimes makes it difficult to identify a single target antigen that is universally expressed in an hematological malignancy. So furthermore, sometimes the antigen expressed on a tumor cell can be also present on the normal tissue. And so you may have a cross-targeting. So let's say, if you have a bispecific against epidermal growth factor receptor, this will target the tumor but will target also the skin with a lot of toxicity. The second challenge is the tumor microenvironment. The solid tumor microenvironment is really complex and often immunosuppressive. It is characterized by the presence of immunosuppressor cells like the T regulators, myeloid derived suppressor cells, and of course the extracellular matrix. All these factors hinder immune cell infiltration and also may reduce dramatically the effectiveness of bispecific antibodies. And as you know, there is also an hypoxic condition in the tumor. The other challenge is related to the poor tumor penetration. As you know also with antibody-drug conjugate, only 1 to 3% of the drug will arrive in the tumor bed. Unlike hematological malignancies where tumor cells are dispersed in the blood and easily accessible, the solid tumors have a lot of barriers, and so it means that tumor penetration can be very low. Finally, the vascularity also of the tumor can be different across solid tumors. That is why some bispecifics have a vascular endothelial growth factor receptor or vascular endothelial growth factor as a target. Of course, what do we have to do to overcome these challenges? First, we have to select the optimal antigen. So knowing very well the biology of cancer and the tumor-associated antigens can really select a subgroup of epitopes that are specifically overexpressed in cancer cells. And so we need to design bispecifics according to the tumor type. Second, optimize the antibody format. So there are numerous bispecific antibody formats. We can consider the dual variable domain immunoglobulin, we specified this in our paper. The single chain variable fragments, so FC variable fragments, and the diabodies that can enhance both binding affinity and stability. And finally, the last point, combination therapies. Because bispecific antibodies targeting immune checkpoint, we have many targeting PD-1 or PD-L1 or CTLA-4, combined eventually with other immune checkpoint inhibitors. And so you may have more immunostimulating effect. Dr. Hope Rugo: This is a fascinating field and it is certainly going to go far in the treatment of solid tumors. You know, I think there is some competition with what we have now for antibody-drug conjugates. Do you see that bispecifics will eventually become bispecific ADCs? Are we going to combine these bispecific antibodies with ADCs, with chemotherapy? What is the best combination strategy do you think looking forward? Dr. Giuseppe Curigliano: So, yes, we have a bispecific ADC. We have actually some bispecifics that are conjugated with a payload of chemotherapy. Some others are conjugated with immunoactivation agents like IL-2. One of the most effective strategies for enhancing bispecific activity is the combination therapy. So which type of combination can we do? First, bispecific antibodies plus checkpoint inhibitors. If you combine a bispecific with an immune checkpoint, like anti-PD-1, anti-PD-L1, or anti-CTLA-4, you have more activity because you have activation of T-cells, reduction of immunosuppressive effect, and of course, the capability of this bispecific to potentiate the activity of the immune checkpoint inhibitor. So, in my opinion, in a non-small cell lung cancer with an expression of PD-L1 more than 50%, if you give pembrolizumab plus a bispecific targeting PD-L1, you can really improve both response rate and median progression-free survival.  Another combination is chemotherapy plus bispecific antibodies. Combining chemotherapy with bispecific can enhance the cytotoxic effect because chemotherapy induces immunogenic cell death, and then you boost with a bispecific in order to activate the immune system. Bispecific and CAR T-cells, until now, we believe that these are in competition, but this is not correct. Because CAR T-cells are designed to deliver an activation of the immune system with the same lymphocytes engineered of the patients, with a long-term effect. So I really do not believe that bispecifics are in competition with CAR T-cells because when you have a complete remission induced by CAR T-cell, the effect of this complete remission can last for years. The activity of a bispecific is a little bit different. So there are some studies actually combining CAR T-cells with bispecifics. For example, bispecific antibodies can direct CAR T-cells in the tumor microenvironment, improving their specificity and enhancing their therapeutic effect.  And finally, monoclonal antibody plus bispecific is another next generation activity. Because if you use bispecific antibodies in combination with existing monoclonal antibodies like anti-HER2, you can potentially increase the immune response and enhance tumor cell targeting. In hematological malignancies, this has been already demonstrated and this approach has been particularly effective. Dr. Hope Rugo: That's just so fascinating, the whole idea that we have these monoclonal antibodies and now we are going to add them to bispecifics that we could maybe attach on different toxins to try and improve this, or even give them with different approaches. I suppose giving an ADC with a bispecific would sort of be similar to that idea of giving a monoclonal antibody with the bispecific. So it is certainly intriguing. We also will need to understand the toxicity and cost overall and how we are going to use these, the duration of treatment, the assessment of biomarkers. There are just so many different aspects that still need to be explored.  And then with that idea, can you look ahead five or ten years from now, and tell us how you think bispecific antibodies will shape our next generation cancer therapies, how they will be incorporated into precision oncology, and the new combinations and approaches as we move forward that will help us tailor treatment for patients both with solid tumors and hematologic malignancies? Are we going to be giving these in early-stage disease in solid tumors? So far, the studies are primarily focusing on the metastatic setting, but obviously one of the goals when we have successful treatments is to move them into the early stage setting as quickly as possible. Dr. Giuseppe Curigliano: Let us try to look ahead five years rather than ten years, to be more realistic. So, personally I believe some bispecifics can potentially replace current approaches in specifically T-cell selected population. As we gather more data from ongoing clinical trials and we adopt a deeper understanding of the tumor immuno microenvironment, of course we may have potentially new achievement. A few days ago, we heard that bispecifics in triple negative breast cancer targeting VEGF and PD-L1 demonstrated an improvement in median progression-free survival.  So, how to improve and to impact on clinical practice both in the metastatic and in the early breast cancer setting or solid tumor setting? First, personalized antigen selection. So we need to have the ability to tailor bispecific antibody therapy to the unique tumor profile of individual patients. So the more we understand the biology of cancers, the more we will be able to better target. Second, bispecific antibodies should be combined. I can see in the future a potential trial in which you combine a bispecific anti-PD-L1 and VEGF with immune checkpoint inhibitor selected also to the level of expression of PD-L1, because integration of antibody bispecific with a range of immunotherapies, and this cannot be only immune checkpoint inhibitors, but can be CAR T-cells, oncolytic viruses, also targeted therapy, will likely be a dominant theme in the coming years. This combination will be based on the specific molecular and immuno feature of the cancer of the patient.  Then we need an enhanced delivery system. This is really important because you know now we have a next generation antibody. An example are the bicyclic. So you use FC fragment that are very short, with a low molecular weight, and this short fragment can be bispecific, so can target at the same time a target antigen and improving the immune system. And so the development of this novel delivery system, including also nanoparticles or engineered viral vectors, can enhance the penetration in the tumor bed and the bioavailability of bispecific antibodies. Importantly, we need to reduce toxicity. Until now, bispecifics are very toxic. So the more we are efficient in delivering in the tumor bed, the more we will reduce the risk of toxicity. So it will be mandatory to reduce off-target effects and to minimize toxicity.  And finally, the expansion in new indication. So I really believe you raised an excellent point. We need to design studies in the neoadjuvant setting in order to better understand with multiple biopsies which is the effect on the tumor microenvironment and the tumor itself, and to generate hypotheses for potential trials or in the neoadjuvant setting or in those patients with residual disease.  So, in my opinion, as we refine design, optimize patient selection, and explore new combination, in the future we will have more opportunity to integrate bispecifics in the standard of care. Dr. Hope Rugo: I think it is particularly helpful to hear what we are going to be looking for as we move forward to try and improve efficacy and reduce toxicity. And the ability to engineer these new antibodies and to more specifically target the right proteins and immune effectors is going to be critical, of course, moving forward, as well as individualizing therapy based on a specific tumor biology.  Hearing your insights has been great, and it really has opened up a whole area of insight into the field of bispecifics, together with your excellent contribution to the ASCO Educational Book. Thank you so much for sharing your thoughts and background, as well as what we might see in the future on this podcast today. Dr. Giuseppe Curigliano: Thank you very much for the invitation and for this excellent interview. Dr. Hope Rugo: And thanks to our listeners for joining us today. You will find a link to the Ed Book article we discussed today in the transcript of this episode. It is also, of course, on the ASCO website, as well as on PubMed. Please join us again next month on By the Book for more insightful views on the key issues and innovations that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:       Dr. Hope Rugo  @hope.rugo  Dr. Giuseppe Curigliano @curijoey Follow ASCO on social media:       @ASCO on X (formerly Twitter)       ASCO on Bluesky      ASCO on Facebook       ASCO on LinkedIn       Disclosures:      Dr. Hope Rugo:   Honoraria: Mylan/Viatris, Chugai Pharma  Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer  Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  Dr. Giuseppe Curigliano: Leadership: European Society for Medical Oncology, European Society of Breast Cancer Specialists, ESMO Open, European Society for Medical Oncology Honoraria: Ellipses Pharma Consulting or Advisory Role: Roche/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol-Myers Squibb, Samsung, AstraZeneca, Daiichi-Sankyo, Boerigher, GSK, Seattle Genetics, Guardant Health, Veracyte, Celcuity, Hengrui Therapeutics, Menarini, Merck, Exact Sciences, Blueprint Medicines, Gilead Sciences Speakers' Bureau: Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, Menarini, Gilead Sciences, Exact Sciences Research Funding: Merck Travel, Accommodations, Expenses: Roche/Genentech, Pfizer, Daiichi Sankyo, AstraZeneca      

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

“Our vision as a company is to help eradicate cancer with tests that prevent it, detect it earlier and guide treatment,” says Kevin Conroy, CEO of Exact Sciences. He joins Bloomberg Intelligence analyst Jonathan Palmer on the Vanguards of Health Care podcast to trace Exact’s journey into a cancer-diagnostics leader. From Cologuard’s initial rise to its recently launched Cologuard Plus test, the debut of Cancerguard and expansion into minimal-residual disease (MRD) testing, Conroy shares how science, technology and culture underpin the company’s next decade.See omnystudio.com/listener for privacy information.

In this episode, Dr. Tom Beer, Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences, shares how blood-based screening could identify dozens of cancers earlier, the steps for thoughtful clinical implementation, and the potential to significantly reduce late-stage cancer diagnoses and mortality.This episode is sponsored by Exact Sciences.

In this episode of The Dish on Health IT, Tony Schueth and Rob Dribbon are joined by Neikisha Charles Director of Quality Improvement and Risk Management of Bedford Stuyvesant Family Health Center (Bed-Stuy), a federally qualified health center (FQHC) in Brooklyn, NY. Together, they dig into common misconceptions about FQHCs and shine a spotlight on the opportunities they present for strategic engagement across the healthcare ecosystem—especially for health IT and life sciences organizations.Neikisha opens with her personal journey: starting as a data analyst at Bed-Stuy in 2021 and quickly rising into her current leadership role because of her knack for using data to drive quality improvement. Her story illustrates the increasing sophistication of FQHCs and sets the tone for a broader conversation about how these organizations are evolving.To help orient listeners who may not fully understand the role of FQHCs, Neikisha provides a clear definition: FQHCs are federally funded community-based providers mandated to offer care to all residents in underserved areas, regardless of insurance status. They are deeply attuned to social determinants of health and committed to removing access barriers for vulnerable populations.Rob adds context from his years in pharma, highlighting the unique value proposition of FQHCs—namely, their holistic and integrated approach to care. He urges listeners not to overlook these organizations simply because they've historically focused on commercial health systems.Neikisha then debunks a major myth: that FQHCs only serve uninsured or homeless patients. In fact, Bed-Stuy primarily serves Medicaid-managed populations, but also sees commercially insured and uninsured individuals, offering services on a sliding scale. Services range from primary care and mental health to dental, podiatry, and optometry, along with extensive care coordination and social support services.When asked what health IT vendors and life sciences companies may be missing, Neikisha makes it clear: FQHCs are not tech or data-poor. Bed-Stuy uses a robust EHR (eClinicalWorks), the Azara DRVS population health platform, and Artera for two-way patient communication. These tools aren't just window dressing—they are integrated into care delivery to close gaps, improve compliance, and monitor population health in real time.She offers a compelling case study: When colorectal cancer screening rates began to drop, Neikisha led a data-driven campaign using Azara to identify noncompliant patients, Artera to send targeted outreach texts, and a partnership with Exact Sciences to offer Cologuard kits to patients by mail. The result? A 12.3% increase in screening compliance over 18 months.Rob underscores the significance of this approach—not just the smart use of technology, but also the community-level relationships and the trust that make this kind of intervention effective.The discussion then shifts to interoperability. Neikisha notes the complexities of data exchange and the importance of dedicated roles like a Director of Health Integration to manage relationships and reporting. Bed-Stuy is connected to a regional health information organization (RHIO), uses platforms like Azara to track transitions of care, and maintains read-only EMR access with key partners to streamline care coordination. While true vendor-agnostic interoperability remains elusive, FQHCs are actively working with what's available.Tony brings the conversation back to the bigger picture: What gaps do vendors and life sciences partners need to close? Neikisha points to the need for better education about what FQHCs actually do and who they serve. She challenges companies to co-create solutions with FQHCs—offering tools that reflect real-world workflows and support sustainable partnerships rather than transactional engagements.The episode wraps with both Rob and Neikisha emphasizing the untapped potential of FQHCs. With over 30 million Americans relying on them for care, these organizations are not fringe players—they are essential infrastructure. And as Neikisha puts it, they're “here to stay.” To partner successfully, the first step is simple: reach out, learn what's needed, and build something meaningful together.Related ContentWhat Are FQHCs, & Should Life Sciences Manufacturers Even Care About Them?HIT Perspectives May 2025: FQHC Myth vs Fact Bedford Stuyvesant Family Health Center Brooklyn NY - Primary Care Services 

In this third episode of the OncoExTra® podcast series, host Ruchika Talwar, MD, talks with Christy Russell, MD, Vice President of Medical Affairs at Exact Sciences, about what oncologists can expect when they receive their OncoExTra comprehensive genomic profiling test results, and how they can utilize the report and tap into Exact Sciences' skilled support team to develop a plan of action for their patients.

PhD to Corporate Finance & M&A? Gabriel Fung's Unconventional Journey!Ever wondered how a PhD in Pathology transitions to high-stakes roles in Equity Research and Corporate Development? In this episode of Careers in Finance on FinPod, Gabriel Fung reveals his unique path from the lab to leading strategic M&A and partnerships at Exact Sciences in the competitive healthcare and biotech sectors. This is a must-listen for PhDs, scientists, and anyone considering a career pivot into finance from a non-traditional background!

In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN) sequencing and why it matters for oncologists. Drs. Mazloom and LoBello discuss PMTN sequencing as a gold standard method for calculating tumor mutational burden and personalized therapy selection and share their thoughts on the future of cancer testing.

In this podcast episode, host Ruchika Talwar, MD, is joined by Amin Mazloom, PhD, Senior Vice President of Bioinformatics, Biostatistics & Data Innovation, and Janine LoBello, DO, Senior Clinical Laboratory Medical Director at Exact Sciences to discuss patient-matched tumor-normal (PMTN) sequencing and why it matters for oncologists. Drs. Mazloom and LoBello discuss PMTN sequencing as a gold standard method for calculating tumor mutational burden and personalized therapy selection and share their thoughts on the future of cancer testing.

In this podcast episode, Ryan Stidham, MD, discusses the evolution and development of digital imaging and AI in the GI space, how AI can revolutionize stages within the clinical trials and practices and more. •    Intro :24 •    The interview/about Stidham :36 •    Tell us about your family and where you grew up. 1:14 •    How did you embrace changes in technology growing up? 3:07 •    What was the seminal moment that got you to move from being a consumer of information to being a producer and innovator?  6:05 •    What ignited you to start commercializing and patenting your ideas, and operationalizing them into a company? How did that evolution occur? 8:32 •    Can you give a quick overview of what these tools and technologies entail?  12:52 •    What got you interested in inflammatory bowel disease, and how did your childhood interest in coding shift to artificial intelligence? 18:12 •    Where did your interest in AI come about? 20:26 •    You recently published a review on how AI will revolutionize the conduct of clinical trials in inflammatory bowel disease […] Will AI remove the need for central reading in IBD trials in the future? 23:58 •    How do we change the way we train GI doctors, and should we start making these changes today? 26:38 •    With AI rapidly changing the landscape, are we spending enough time educating our fellows in how to adapt to changes and communicate with patients? 32:33 •    What do you think will change in IBD and gastroenterology in the near term as a result of AI? 35:06 •    What is it that we really need in terms of health care access, and how can AI technology assist these needs? 38:39 •    Thank you, Ryan 44:04 •    Thanks for listening 44:20 Ryan Stidham, MD, MS, AGAF, is a translational scientist caring exclusively for patients with inflammatory bowel disease. He is an associate professor in the department of medicine and the department of computational medicine and bioinformatics where he serves as the associate chair of translational research. His research focus is the use of artificial intelligence to improving measurement of IBD and other gastrointestinal diseases, developing new interpretations of cross-sectional imaging, endoscopy, medical text, and other electronic data.  We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Stidham, follow @CrohnsDoc on X. Disclosures: Berry and Chey report no relevant financial disclosures. Stidham reports consulting or on advisory boards for AbbVie, Bristol Myers Squibb, CorEvitas, Eli Lilly, Exact Sciences, Gilead, Janssen, Merck, Pfizer, and Takeda. Stidham holds intellectual property and equity on medical imaging and endoscopic analysis technologies licensed by the University of Michigan to PreNovo, LLC, AMI, LLC and PathwaysGI, Inc.

In today's episode, supported by Exact Sciences, we had the pleasure of speaking with Eric Christenson, MD, about the Oncodetect test, which is available for use in molecular residual disease detection in patients with solid tumors. Dr Christenson is an assistant professor of oncology at the Johns Hopkins School of Medicine in Baltimore, Maryland. In our exclusive interview, Dr Christenson discussed the capabilities of Oncodetect, its clinical applications, key findings from the Alpha-CORRECT study, and the prognostic value of this test.

Die Diagnose Brustkrebs trifft jedes Jahr zehntausende Frauen wie ein Schock. Mehr als 70.000 Neuerkrankungen werden jährlich in Deutschland registriert; es handelt sich damit um die häufigste Krebsform bei Frauen und insgesamt die dritthäufigste Art von Krebs. Es gibt jedoch eine Vielzahl von Behandlungsmöglichkeiten, die im Idealfall möglichst individuell auf die einzelne Patientin zugeschnitten sind.

As the Gut Doctor podcast continues to raise awareness for colorectal cancer, Dr. Parikh interviews Dr. Paul Limburg, MD, who is a gastroenterologist and chief medical officer for Exact Sciences. They discuss colon cancer prevalence, barriers to CRC screening, and the role of stool based testing such as Cologuard. This episode is sponsored by Exact Sciences whose purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Exact Sciences is the maker of the Cologuard® test, a stool-based screening test for average risk adults ages 45 and over. 

How is France navigating and influencing today's complex geopolitical landscape? What strategy is President Macron deploying to end war in Europe? How do France and Norway collaborate on key global challenges? How is France leveraging AI to support its goals? Listen to the conversation with: Florence Robine, the French Ambassador to Norway Paal Frisvold, expert on European Affairs in Norway Mette Vågnes Eriksen, Secretary General, the Norwegian Polytechnic Society In this episode, you will gain insight to France's key priorities for strengthening European cooperation and the NATO alliance. You will hear practical examples from both the civil and military sectors, covering energy, the Arctic, and security. The participants also reflect on the actions of President Macron, one of the world's most influential heads of state and Europe's most-followed leader on social media. Additionally, you will discover how the French Navy helps safeguard Norwegian waters and explore the rich trade and cultural ties between our two nations. Get to know Ambassador Florence Robine, who holds a PhD in Epistemology and the History of Exact Sciences and Scientific Institutions. She has been awarded the prestigious French Legion of Honour and serves as an Associate Professor of Physical Sciences. A true Ambassadrice Polytechnique. Hosted on Acast. See acast.com/privacy for more information.

In this podcast episode, Prateek Sharma, MD, about how program directors can help shepherd GI fellows into clinical research spaces, providing quality exams for upper endoscopy and more. •    Intro :24 •    The interview/about Sharma :43 •    Tell us about your family and where you grew up. 1:00 •    Did you encourage your son to go into medicine? 2:17 •    What kinds of doctors were your parents?  3:40 •    Who were your big, early influences? 4:08 •    If you didn't always want to be a doctor, what convinced you to change your mind?  6:11 •    When did you make the decision to go into academic medicine as a career? 7:16 •    Are you seeing fewer and fewer fellows interested in pursuing a career in academic medicine? […] Are there ways to counsel fellows to be more interested in this type of work? 9:49 •    How long have you been a program director, and are you still enjoying the work? 13:58 •    How did you choose to into internal medicine and GI?  17:22 •    As leaders of academic research centers, what have you done or plan to do in the face of potential cuts to the NIH overhead rates? 18:40 •    How are we doing right now as a country and globally in terms of early detection of Barrett's neoplasia? 22:08 •    Why has performing high-quality surveillance and screening of procedures like colonoscopy been so much more successful than performing high-quality exams for upper endoscopy? 25:33 •    If the biggest hurdle to performing these exams is time, do you feel that more education around how to perform a high-quality exam will move the needle, or are other incentives needed? 28:32 •    Do you think AI-based detection is overhyped or underhyped in GI? 30:33 •    What are your thoughts on DNA-based testing for conditions like Barrett's neoplasia, and how should they be incorporated into standard practice? 34:24 •    What are your priorities as president of the American Society of Gastrointestinal Endoscopy this year? 38:42 •    What do you see as the biggest threats or concerns to gastroenterologists? 42:25 •    Final thoughts? 46:32 •    Thank you, Prateek 47:13 •    Thanks for listening 47:15 Prateek Sharma, MD, FASGE, FACP, FACG, is professor of medicine and director of the GI fellowship program at the University of Kansas School of Medicine. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Sharma, follow @KUcancercenter and @ASGEendoscopy on X and Instagram. Disclosures: Berry and Chey report no relevant financial disclosures. Sharma reports consulting for Boston Scientific Corporation, CDx Labs, Cipla, Exact Sciences, Medtronic, Olympus Corporation, Salix Pharmaceuticals, Samsung Bioepis and Takeda and provides grant/research support to ERBE USA Inc., Fujifilm Holdings America Corporation, Ironwood Pharmaceuticals Inc. and NEC.

Join us as we navigate the evolving landscape of colorectal cancer (CRC ) screening. In this episode, our expert faculty Drs. Wendy Wright and Roseann Velez delve into the critical importance of early CRC detection — especially in younger patients. We'll explore the latest expert consensus guidelines, the array of screening tests available and the barriers to effective screening. With robust data and real-world insights, this podcast aims to empower nurse practitioners with knowledge and tools to improve CRC screening uptake and outcomes. Tune in to learn how proactive screening can save lives and reduce the burden of CRC. To claim 1.0 contact hours of continuing education (CE) credit for this program, (Early Detection Saves Lives: Navigating the Evolving Landscape of Colorectal Cancer Screening), search for this program by the title and complete the post-test and evaluation by entering the participation code given after listening to the podcast. This podcast was supported by an independent medical education grant from Exact Sciences. Download the patient handout here

In this podcast episode, Ruchika Talwar, MD, sits down with Rick Baehner, MD, Chief Medical Officer of Precision Oncology at Exact Sciences and Clinical Professor of Pathology at University of California, San Francisco, to discuss the importance of ultra-comprehensive genomic profiling in advanced cancer therapy selection. The two talk about the OncoExTra® test from Exact Sciences, which includes whole-exome DNA sequencing and whole-transcriptome RNA sequencing, and how the latest updates to industry guidelines will continue to influence approaches to cancer care.

In this episode, host Shikha Jain, MD, speaks with David Gandara, MD, about how ctDNA and CAR-T cell therapies are transforming precision medicine, the importance of patient reported outcomes and more. •    Welcome to another exciting episode of Oncology Overdrive 0:14 •    About Gandara 0:19 •    The interview 1:02 •    Can you tell me a little more about what you are working on now? 1:25 •    How did you get engaged with the community in Hawaii?  6:30 •    What do you think is going to happen with ctDNA moving forward? 8:29 •    Can you utilize ctDNA and minimal residual disease information to determine how long patients need to be on adjuvant therapy?  11:42 •    How did you get into the ctDNA space?  15:06 •    How do you see AI transforming health care beyond providing patients with more information and taking more ownership of their health?  18:28 •    Can you tell us more about how a second opinion clinic works? How did this type of clinic develop and become part of what you do?  23:17 •    What are some of your predictions as to what will happen in oncology care over the next ten to twenty years?  29:00 •    If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 37:30 •    How to contact Gandara 38:47 •    Thanks for listening 39:10 David Gandara, MD, is a clinician-scientist and lung cancer specialist internationally recognized for his expertise in thoracic cancers, cancer drug development and biomarker development. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dr. Gandara can be reached via email drgandara@ucdavis.edu.  Disclosures: Jain reports no relevant financial disclosures. Gandara reports institutional research grants from Astex, Amgen and Genentech; institutional consulting for AstraZenica, Exact Sciences, Genentech, Guardant Health, IO Biotech and Oncohost; consulting for Adagene, Henlius USA, Foundation Medicine and Sanofi; serves on the advisory board of Abbvie, Janssen, Merck, Mirati, Regeneron and Revolution Medicine. 

In healthcare marketing, product and marketing are inseparable. But in many industries, marketers have become disconnected from the products they promote. What does this mean for marketing effectiveness?Exact Sciences CMO Jaime LaMontagne joins Elena and Angela to explore how staying connected to product drives better marketing outcomes. Drawing from her extensive healthcare marketing experience, Jaime shares advice on balancing multiple stakeholders, strict regulations, and evolving patient expectations.Topics covered: [01:00] Why healthcare marketers must understand their products deeply[06:00] Using claims matrices to communicate with different stakeholders[14:00] Balancing creative marketing with healthcare regulations[18:00] How patient empowerment is changing healthcare marketing[23:00] The importance of both brand building and demand capture[30:00] Why marketers should "call their baby ugly"  To learn more, visit marketingarchitects.com/podcast or subscribe to our newsletter at marketingarchitects.com/newsletter.  Resources: 2024 MarketingWeek Article: https://www.marketingweek.com/ritson-liquid-death-product/Jaime LaMontagne's LinkedIn: https://www.linkedin.com/in/jaime-lamontagne-marketing100/Exact Sciences: https://www.exactsciences.com/ Get more research-backed marketing strategies by ubscribing to The Marketing Architects on Apple Podcasts, Spotify, or wherever you listen to podcasts.

In this episode, Scott Becker explores the latest developments in gastroenterology, including the CMS reimbursement boost for Cologuard® by Exact Sciences and the growing adoption of GI Genius™ technology. While these innovations enhance colon cancer screening, colonoscopies remain the gold standard, underscoring their critical role in patient care.

In this episode, Scott Becker explores the latest developments in gastroenterology, including the CMS reimbursement boost for Cologuard® by Exact Sciences and the growing adoption of GI Genius™ technology. While these innovations enhance colon cancer screening, colonoscopies remain the gold standard, underscoring their critical role in patient care.

In this episode, Scott Becker explores the latest developments in gastroenterology, including the CMS reimbursement boost for Cologuard® by Exact Sciences and the growing adoption of GI Genius™ technology. While these innovations enhance colon cancer screening, colonoscopies remain the gold standard, underscoring their critical role in patient care.

Our guest, Raye Arce with Exact Sciences joins us today as we discuss Colon Cancer or Colorectal Cancer. We will explore the various screening options available, including the non-invasive, at-home testing and the traditional colonoscopy. Ray will unpack the key factors influencing these choices, such as frequency, patient preferences, and the importance of early detection, which significantly improves survival rates. Additionally, Ray will provide insights into overcoming the barriers to screening and emphasize the importance of shared decision-making with healthcare providers. Tune in as we discuss how regular screening can make a life-saving difference and what you need to know to take charge of your health. Website: https://www. exactsciences.com SeniorLivingGuide.com Podcast sponsored by TransMed Care Long Distance Medical Transportation The background music is written, performed and produced exclusively by purple-planet.com.https://www.purple-planet.com/ *SeniorLivingGuide.com Webinars and Podcast represents the opinions and expertise of our guests. The content here is for informational and educational purposes. It does not necessarily represent the views, recommendations, opinions or advice of Fairfax Publishing/SeniorLivingGuide.com or its employees 

Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. He explains who may be eligible for these tests, how to interpret results to avoid unnecessary intervention from over-detection, and the varying sensitivity levels of MCED tests across different cancers. Additionally, Tom shares insights into the Falcon trial – a major real-world study assessing a MCED test clinical performance and potential impact on early cancer detection and patient outcomes. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

Episode Summary:In this episode, Maribel Lopez speaks with Roni Jamesmeyer about the changing role of AI in healthcare. Roni Jamesmeyer, the the Senior Healthcare Marketing Manager for Five9, has over twenty years of experience in IT sales, giving her an understanding of the complexity of healthcare delivery. She focuses on Five9's healthcare strategy to help health systems, payers, and life sciences move their contact centers to the cloud and close the gaps in patient communications. Maribel and Roni discuss technological advancements in AI, different uses of AI in healthcare, and Roni's research findings.Key Themes:Maribel and Roni open the episode by discussing the healthcare industry's past attempts to improve the patient experience and how its goals have shifted. Currently, Roni is seeing healthcare companies working toward an omnichannel experience for their customers – meaning that they can interact over many communication channels. AI is helping the industry move forward. Intelligent Virtual Agents (IVAs) improve operations in four major ways: security, patient experience, revenue generation, and reduced administrative backend work. Different companies may focus more on some of these categories than others, but all four functions are extremely important to the healthcare industry. Roni also discusses her AI research findings. She found that AI tuning is crucial to improvement, allowing models to pick up and retain information. As these models are used, they become more personalized and more intelligent and can take on more work as a result. She also found that AI agents open up phone lines, allowing previously missed calls to be answered. Visit Maribel Lopez's Website: https://www.lopezresearch.com/ Follow Maribel Lopez on X/Twitter: https://x.com/maribellopez Subscribe to Maribel Lopez on YouTube: https://www.youtube.com/c/MaribelLopezResearch Follow Maribel Lopez on LinkedIn: https://www.linkedin.com/in/maribellopez/ Learn More About Five9: https://www.five9.com/ Download AI in Healthcare: How AI Drives Value for Five9 Customers: https://www.five9.com/resources/ebook/how-ai-drives-value-healthcare-customers#:~:text=Partners-,AI%20in%20Healthcare%3A%20How%20AI%20Drives%20Value%20For%20Five9%20Healthcare,customer%20surveys%2C%20and%20analyst%20insight. Attend Roni's Webinar with Exact Sciences: https://www.five9.com/registration/2024/exact-sciences-webinar Follow Roni Jamesmeyer on LinkedIn: https://www.linkedin.com/in/roni-jamesmeyer-5733461/ 

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Delays in clinical trials can cost up to $8 million per day, making it crucial to understand and address the main factors causing these setbacks. Strategies to keep clinical trials on schedule include identifying common issues that slow down studies, addressing challenges effectively to minimize risks, and understanding potential financial losses to avoid them. By taking control of clinical trial timelines, researchers can prevent costly delays and ensure successful completion of studies.Senseonics has received FDA clearance for a continuous glucose monitoring (CGM) device that can be worn for up to 365 days. Boston Scientific has closed its acquisition of Silk Road Medical, while Smiths Medical has recalled airway tubes due to a defect that has caused more than 10 injuries. Medtech firms have cut over 14,000 jobs in the past 18 months. Exact Sciences has announced that data supports its colon cancer blood test, which could compete with Guardant Health's similar test. Bausch + Lomb is considering a sale, with private equity firms being potential buyers. The wearables market is expected to grow by 13% annually between 2024 and 2030.Merck's ADC data shows promising results in a lung cancer trial, while Ascendis' trial data puts pressure on Biomarin. Nura Bio secures $68 million in funding for neuroprotective brain drugs. The Biosecure bill could lead to drugmakers pivoting towards China. ESMO24 highlights include a cancer cachexia drug and the impact of immunotherapy on survival rates. Drug development leaders are turning to AI to drive efficiency.Cigna is suing the FTC over a report on pharmacy benefit managers, while employer health costs are expected to rise by 5.8% per employee in 2025. Johns Hopkins has appointed a new cybersecurity chief, and healthcare worker strikes are being tracked, such as nurses at Brigham and Women's Faulkner Hospital planning a strike. Employers are making cost-cutting changes to health plans, and the impact of mentorship in healthcare is highlighted.Pizza Hut is using its pizza boxes to help job seekers get noticed by putting resumes on them. Frito-Lay's campaign targeted at Gen Zers encourages fans to cheat on Flamin' Hot Cheetos with other brands. The US ad spending rebound is proving to be robust beyond cyclical events, such as the Olympics. However, customers don't trust AI, which could be hurting businesses as it decreases purchasing intention.The pharmaceutical industry is facing challenges in expanding patient access and improving cancer research outcomes. Compassionate use, also known as expanded access, provides unapproved drugs to terminally ill patients as a last resort. Radiopharmaceuticals have seen a resurgence in activity and interest from big pharma for treating cancer. Ratio Therapeutics advocates for compassionate use due to the low-risk, high-reward nature of radiopharmaceuticals. Despite challenges like patient safety and ongoing clinical trials, radiopharmaceuticals are gaining momentum in the industry. Big pharma companies are embracing this trend, with smaller players also making waves in the market. The industry is exploring strategies for better site selection in clinical trials and enhancing efficiency during gene therapy development.

In this second part of our discussion, we delve deeper into the innovative approaches and technologies being implemented to address the evolving challenges in cancer care. Panelists will share their experiences with AI-powered tools, virtual reality applications, and personalized treatment plans. We'll also explore the role of patient advocacy in shaping the future of cancer care and the importance of collaboration between healthcare providers, researchers, and technology companies.This episode is sponsored by Exact Sciences.

This podcast discusses the increasing challenges faced by healthcare organizations in providing cancer care due to rising patient numbers and complex treatment needs. Panelists share their experiences and strategies for addressing these challenges, including leveraging technology, expanding access to care, and prioritizing patient advocacy. The discussion also highlights the importance of a collaborative approach between healthcare providers and technology companies to improve patient outcomes. This episode is sponsored by Exact Sciences.

New opportunities are emerging for dedicated biomarker testing navigators facilitated by laboratory professionals to better streamline sample collection and optimize test ordering and results for patients with cancer. In this episode, CANCER BUZZ TV speaks with Lynnette Pineault, MBA, SCT (ASCP), chair of the American Society for Clinical Pathology (ASCP) Biomarker Testing Navigation Feasibility Study and manager of Laboratory Operations and Genetic Counseling Services, Medical Library and Pathology Services, at HealthPartners – Regions Hospital, who shares insights on reshaping multidisciplinary cancer care team workflows to enable laboratory professionals to improve biomarker testing efficiency. “We see these roles [dedicated biomarker testing navigators] playing across and matrixing to support the sample [biomarker testing specimen] along its pathway, so the patient and the sample get to their destination and their treatment/follow-up at the appropriate times together.”—Lynnette Pineault, MBA, SCT (ASCP) Lynnette Pineault, MBA, SCT (ASCP) Chair, ASCP Biomarker Testing Navigation Feasibility StudyManager, Laboratory Operations and Genetic Counseling Services Laboratory Medicine and Pathology Services HealthPartners – Regions Hospital St. Paul, MN   This video podcast was produced in partnership with the American Society for Clinical Pathology and by support from Amgen, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Exact Sciences, and Merck.    Resources: ASCP Explores Innovative Cancer Biomarker Testing Navigator Role (criticalvalues.org) ACCC Cancer Diagnostics Education Program Precision Medicine Stewardship (accc-cancer.org)  

Bryan Goettel is the director of advocacy and alliance relations for Exact Sciences, a Madison, Wisconsin, based biotechnology company. Exact Sciences is perhaps best known for its signature product, Cologuard, an at-home colorectal cancer early detection test for adults of average risk age 45 and older. Further Together host Michael Holtz has a history with the company, including sharing his cancer journey at the first-ever national sales meeting for Cologuard in July 2014 and attending the Cologuard Classic golf tournament as a cancer advocate this past spring. Exact Sciences is on the forefront of oncology treatment and cancer prevention. During this conversation, Goettel talks about where Exact Sciences is heading in the biotechnology space, how he got to be part of the company, the importance of the patient voice in shaping its products, and how companies like ORAU can join the fight against cancer. To learn more, visit https://www.exactsciences.com/

In this podcast episode, John Inadomi, MD, chair of the department of internal medicine at University of Utah Health, discusses the value of mentorship, qualities a leader should possess and more. •    Intro :59 •    Welcome to this episode of Gut Talk 1:23 •    The interview/about Inadomi 1:30 •    Tell us about your family and where you grew up. 2:59 •    Inadomi on the impact World War II had on his family. 3:47 •    Chey and Inadomi on the ways immigrants approached being American post-World War II. 4:33 •    How did you end up in medicine after receiving a mechanical engineering degree from MIT?  6:32 •    How did you go from bionics to polyps/GI? 8:00 •    What did you learn from your experiences playing water polo in college? 10:31 •    How did you end up at the University of New Mexico? 13:00 •    What did Amnon Sonnenberg, MD, MSc, teach you? 16:04   •    How do you view and embrace change? 18:27 •    When did you catch the bug of wanting to lead faculty? […] Did you have mentorship specifically on health system leadership? 24:30 •    How have you learned these leadership characteristics and skills that are not an inherent part of physician training? Do you think there is going to be a change in leadership development moving forward? 29:59 •    For people thinking about advancement opportunities in leadership, what is the mindset you have to develop as a successful division chief or a successful department chair? 33:55 •    What do you think are the biggest challenges facing academic gastroenterology or academic internal medicine? […] How can we physicians be aware of and mitigate these challenges? 38:36 •    How are academic medical centers going to survive?  41:39 •    Do you see the loss of physician autonomy and burnout getting better? 43:29 •    What has been your favorite golf course that you have played on? 46:36 •    Thank you, John 47:48 •    Thanks for listening 48:14 John M. Inadomi, MD, is the Jon M. Huntsman presidential endowed chair, and the chair of the department of internal medicine at University of Utah Health. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. For more from Inadomi, follow him on X @InadomiJ. Disclosures: Berry and Chey report no relevant financial disclosures. Inadomi reports grant support from Exact Sciences.

Learn the business and management skills you need by enrolling in the University of Tennessee Physician Executive MBA program at nonclinicalphysicians.com/physicianmba. Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs. =============== Dr. Maria Abunto is the Senior Manager of Medical Science Liaisons at Exact Sciences, a molecular diagnostics company specializing in the detection of early-stage cancers. Before that, she was a Global Medical Science Liaison for Stryker. She previously worked as an epidemiologist and investigator for the NIH and as a medical scientific expert on the IRB at a large children's hospital. She holds a master's degree in public health from the University of Pittsburg and completed her medical degree at the University of the East in Manila, Philippines. Maria has been an active member of the Medical Science Liaison Society, and mentors other physicians interested in pursuing jobs as an MSL. She frequently lectures on the topic. Because of her expertise, she was asked to present at the 2023 Nonclinical Career Summit on this topic. Today's podcast episode is an excerpt from that lecture. In it, she describes the duties of an MSL, the pros and cons of the job, the salary to be expected, and tips for pursuing your first position as an MSL. You will find all of the links mentioned in the episode at https://nonclinicalphysicians.com/first-nonclinical-msl-job/

Dr. Travelle Franklin-Ford Ellis, talks about her extraordinary shift from an MD/PhD candidate to a vanguard of health equity at Exact Sciences.Dr. Nii and Dr. Travelle talk about:Not matching into residency even with an MD/PhD.10 years of medical school and ending up not practicing on patients.What next after not matching?Advice to premeds who are trying to figure it out.Taking risks in medicine.SIGN UP FOR OUR NEWSLETTER! Have a question for the podcast?Text us at 833-230-2860Send us a message HERE! Twitter: @drniidarkoInstagram: @docsoutsidetheboxEmail: team@drniidarko.comPodcasting Course: www.docswhopodcast.comMerch: https://docs-outside-the-box.creator-spring.comThis episode is sponsored by Locumstory. Learn how locum tenens helps doctors make more and have the lifestyle they deserve!. Check them out HERE!

In this episode of the show, we explore the concept of purposeful branding in healthcare technology and its potential to drive both business success and positive change. Our guests, Steffany Whiting, Executive Vice President of Marketing at iMethods, and Matthew Piette, former Head of Brand Marketing at Exact Sciences and Director of Brand for Philips, share their insights and experiences in building and maintaining purposeful brands in the healthcare industry. In this episode we cover: Defining purposeful branding and its unique application in healthcare How iMethods has built a strong purposeful brand and the impact it has had on their business Innovative programs for engaging employees in a company's mission Challenges of embedding a purposeful culture in larger organizations Making brand purpose real and measurable through patient testimonial videos and measurable goals The ROI of a meaningful mission The role of individual employees in becoming purposeful brand ambassadors Advice for healthcare technology marketers looking to embrace purposeful branding Steffany delves into how iMethods has built a strong, purposeful brand by focusing on changing lives, serving the community, and living out its core values. She discusses the impact this approach has had on employee retention, client loyalty, and business growth, and shares some of the innovative programs iMethods has implemented to engage employees in the company's mission. Matthew brings his experience from larger organizations, discussing the challenges of embedding a purposeful culture in these companies and the importance of senior leadership understanding and communicating the brand's purpose. He also shares examples of how Exact Sciences and Philips have made their brand purpose real and measurable through patient testimonial videos and measurable goals. Together, Steffany and Matthew offer valuable insights and advice for healthcare technology marketers looking to embrace purposeful branding in their organizations. They discuss the unique application of this concept in healthcare, the ROI of a meaningful mission, and the role of individual employees in becoming purposeful brand ambassadors. This episode is a must-listen for anyone interested in the power of purposeful branding to drive both business success and positive change in healthcare.

In this MM+M Fast Break, Jack O'Brien talks with former NBA All Star and Kentucky Wildcats legend Jamal Mashburn about working with Exact Sciences on the company's Box Out Colon Cancer campaign.He discusses his personal connection to colorectal cancer, his involvement in the awareness push and his Final Four predictions.  Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

As the need for access to guideline-concordant biomarker testing for underserved populations continues to grow, hear what care teams need to know about coverage for Medicaid beneficiaries and the legislative outlook for 2024. In this episode, CANCER BUZZ speaks with Hilary Gee Goeckner, MSW, director of State and Local Campaigns for the American Cancer Society Cancer Action Network (ASC CAN), who shares policy perspectives and the latest on state legislation to expand coverage for biomarker testing for Medicaid beneficiaries.    “There are a lot of challenges around implementation—getting the legislation passed is just the first step…It is also important for providers to be aware of the new rules that affect many plans and their states so they are able to order testing that may not have been covered or rejected previously.” –Hilary Gee Goeckner, MSW   Hilary Gee Goeckner, MSW Director, State and Local Campaigns, Access to Care American Cancer Society Cancer Action Network Washington, D.C. This episode was developed in connection with the ACCC education program Improving Access to Biomarker Testing in Medicaid Populations and is made possible with support by Foundation Medicine and Exact Sciences. Resources: The Cost of Biomarker Testing: Moving from Support-Based to Sustainable Solutions  Comprehensive Cancer Care: The Role of Biomarker Testing  Biomarker Testing for Medicaid Beneficiaries (Podcast)  Access to Biomarker Testing - American Cancer Society Cancer Action Network   The Road to Comprehensive Biomarker Testing for All – ACCC Buzz Blog  Improving Access to Biomarker Testing in Medicaid Populations  Precision Medicine in Rural and Underserved Areas – ACCC Buzz Blog  Patient Perceptions of Biomarker Testing – Oncology Issues  Cancer Diagnostics - Biomarkers  Eliminating Precision Medicine Disparities    

Welcome to Off The Tap! Join us this week as we drink Dublin Me Luck brewed at 11 Below Brewing Company in Houston, Texas and discuss topics like St. Patrick's Day Do's & Don'ts, Exact Sciences, “As Seen on TV”, and more. If you enjoy the content, follow us on social media to watch clips and stay up to date on episode releases! Twitter: @offthetappod Instagram: @offthetappodcast TikTok: @offthetappod Facebook: @offthetappodcast

Are you ready to level up and learn from uncomfortable experiences? In this episode of the HR Mixtape podcast, host Shari Simpson is joined by guest Kyra Matkovich to tackle some juicy HR questions sourced from the internet. They discuss topics such as addressing discrepancies in employee information, renaming holiday events for inclusivity, dealing with condescending behavior from a C-suite leader, handling an employee with a drinking problem, and navigating a challenging relationship with an internal candidate. Three key takeaways from this episode are: When addressing discrepancies in employee information, it's important to approach the conversation with sensitivity and offer support rather than make assumptions or judgments. Inclusive language and renaming events can help create a more welcoming and inclusive workplace environment, especially when it comes to holiday celebrations. Dealing with challenging behavior from a C-suite leader requires open and honest communication, setting clear expectations, and documenting any inappropriate incidents. It's crucial to prioritize the well-being of employees and hold leaders accountable for their actions. Overall, this episode provides valuable insights and practical advice for HR professionals facing various HR challenges in the workplace. Guest(s): Kyra Matkovich, Principal Human Resources Business Partner, Exact Sciences

Welcome to Becker's Healthcare Podcast, where we delve into the fascinating world of genetic counseling in oncology. Sponsored by Exact Sciences, this episode features Megan Inger, a licensed certified genetic counselor specializing in oncology at Ohio Health. Megan discusses her journey into genetic counseling, emphasizing the profound connections she forms with patients. She highlights the pivotal role genetic counselors play in identifying individuals for genetic testing, interpreting complex results, and supporting patients throughout their cancer journey. Megan also explores the transformative impact of comprehensive genomic profiling on cancer care, sharing real-life examples where genetic knowledge altered lives. Join us in unlocking the empowering role of genetic counseling in oncology decisions with Megan Inger on this insightful episode.This episode is sponsored by Exact Sciences.

November 22: Today on the Conference channel, it's an Interview in Action live from the 2023 CHIME Fall Forum. On this episode Sue Schade, Principal at StarBridge Advisors speaks with Cherodeep Goswami, Chief Information & Digital Officer at The University of Wisconsin Health System and Nassar Nizami, Chief Information Officer at Exact Sciences. What's in store for Exact Sciences, a renowned clinical research company mainly known for their product ColoGuard? How is UW Health working towards deploying automation?Subscribe: This Week HealthTwitter: This Week HealthLinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

In this episode of Life Science Success, my guest is Bob Rochelle the Chief Commercial Officer at Cleveland Diagnostics.  Bob is a proven expert in launch, strategy, and marketing for novel healthcare products. His more than 30 years of experience ranges from start-ups such as Exact Sciences and Good Start Genetics to established multinationals such as Abbott Laboratories.   Introduction of Bob Rochelle: The episode of "Life Science Success" features Bob Rochelle, Chief Commercial Officer at Cleveland Diagnostics. Rochelle is recognized for his expertise in launch strategy and marketing for novel healthcare products. Bob Rochelle's Background: With 35 years in the healthcare industry, Rochelle has extensive experience, primarily in diagnostics, working with both pharmaceuticals and startups. His career includes roles in various therapeutic and diagnostic areas, from antibiotics and antihypertensive drugs to genetic disease diagnostics and cancer. Transition to Startups: Rochelle discusses his transition from large corporations like Abbott Laboratories to smaller startups. He emphasizes the appeal of being able to rapidly implement ideas and the challenges of limited resources compared to larger companies. Cleveland Diagnostics and Novel Technology: At Cleveland Diagnostics, Rochelle is involved with a novel platform technology for cancer diagnostics. He highlights the importance of innovative technology and a strong team in his career choices. Insights on Cancer Diagnostics and Career Lessons: Rochelle shares insights on the evolution of cancer diagnostics, emphasizing the importance of specificity and sensitivity in tests like isopsa for prostate cancer. He reflects on lessons learned throughout his career, including the significance of diverse perspectives in small companies and the challenges of navigating healthcare reimbursement systems.

Exact Sciences Corporation, Q3 2023 Earnings Call, Nov 01, 2023

Welcome to Life in the Leadership Lane where I am talking to leaders making a difference in the workplace and in our communities. How did they get to where they are and what are they doing to stay there! Buckle up and get ready to accelerate in the Leadership Lane! This week, I am talking with Kyra Matkovich, SHRM-CP, PHR, Principal Human Resources Business Partner at Exact Sciences. How did Kyra get started in her career? What led her to the world of HR and Leadership? What does Kyra share about mentors that have inspired her journey? When did Kyra “find her lane” in her career? What does Kyra share about “HR Coffee Shot”? What does Kyra share about “leadership”? What does Kyra share about the importance of "laughter”? What does Kyra share about being intentional? What does Kyra share about “HR Shenanigans”? What does Kyra share about volunteer leadership? What advice does Kyra share to help us in our every day? …and more as we spend “Time to Accelerate” with a few more questions. Interview resources: Favorite quote(s) from Kyra: “The greatest resources you have are the people around you.” “Laughter is a way we connect with people.” Connect with Kyra on LinkedIn Learn more about Kyra's Blog here HR Shenanigans Check out Bruce's books Life in the Leadership Lane; Moving Leaders to Inspire and Change the Workplace Find Your Lane; Change your GPS, Change your Career (“Book Authority” Best Books) Milemarkers; A 5 Year Journey …helping you record daily highlights to keep you on track. Subscribe to Bruce's Blog “Move to Inspire” Connect with Bruce on LinkedIn Connect with Bruce on Twitter Connect with Bruce on Instagram Connect with Bruce on Facebook Get relocation support for your next household goods or commercial office move across the US by reaching out to Bruce at bwaller@goarmstrong.com or visit The Armstrong Company

Join Dr. Rick Baehner, Chief Medical Officer of the Precision Oncologydivision at Exact Sciences, in this episode of Becker's Healthcare Podcast. Dr.Baehner discusses the evolving landscape of precision oncology and how ExactSciences is equipped to address the dynamic challenges and opportunities inmolecular testing for cancer patients. He shares key milestones that highlight thecompany's commitment to innovation. Exploring the role of technology in cancerprevention, early detection, and improved treatment guidance, Dr. Baehner explainshow Exact Sciences aligns with these objectives while addressing the concerns ofcancer leaders. Discover what exciting goals and developments are on the horizonfor Exact Sciences and tune in for Dr. Baehner's closing thoughts on this insightfuljourney.This episode is sponsored by Exact Sciences.Cologuard is intended to screen adults 45 and older at average risk for colorectalcancer. Rx only. Please see Cologuard Indications and Important Risk Information atCologuardhcp.com/risk-information. Exact Sciences' MCED and MRD tests are underdevelopment. The features discussed in this podcast describe current developmentgoals. It has not been cleared or approved by the US Food and Drug Administrationor any other national regulatory authority.

Sarah Condella, executive vice president of human resources at Exact Sciences, shares what creating a best-in-class workplace culture means for the customer experience and an engaged workforce.

Kevin Conroy, CEO of Exact Sciences, on early detection of cancer.

Stocks may be taking a breather after their recent run, but our special guest says she's more bullish on the market than she's been in a long time. She lays out her case and gives us her strategy. Plus shares of FedEx dropping after missing revenue estimates for its latest quarter. And the CEO of Exact Sciences on the company's latest colorectal cancer test results. Fast Money Disclaimer

Today, Tasha Keeney sits down with Simon Barnett to talk about ARK's valuation of Exact Sciences and to share our outlook about the company's trajectory in the next five years. Exact Sciences is the cancer testing company that has brought to market both Cologuard and Oncotype. This conversation covers the prominence and acceptance of these two testing franchises, Exact Sciences' product leadership, Exact's recent performance in the market, the models that ARK has developed for gauging the company's outlook, and the areas of risk that investors should be aware of. One of the main focuses of today's chat is what Exact Sciences' progress symbolizes in terms of the future of the cancer treatment field, with Simon making an argument for why he sees them holding onto their market-leading position for the foreseeable future. We also spend some time at the end of the episode considering what this means for healthcare and individual wellbeing in general, so make sure to catch it all in this episode of For Your Innovation! Please refer to the Exact Sciences valuation article for a more comprehensive explanation of ARK's model, including its risks and limitations. “Cancer care is something that is totally divorced from interest rate changes or consumer sentiment. It's something that's very predictable, and it's something that's very important.” — @sbarnettARK Key Points From This Episode: Introducing Exact Sciences and its two biggest testing franchises: Cologuard and Oncotype. Valuation of Exact Sciences and how ARK has approached creating these models. Calculations for the price target of the company. Sales and marketing at Exact Sciences and the positive brand recognition they have built. Benchmarks for analyzing companies like Exact Sciences. Comparing ARK's process and view on Exact Sciences to other opinions in the market. How the lowered price of genome sequencing has affected the outlook for the market. The route to the aggregate gross margin structure for Exact Sciences. Qualitative elements that matter most to ARK; how Exact Science fits into our rubric. Alignment between the expectations of Exact Science's management and our estimations. A look at the three main areas of risk: competition, time, and financing. Simon explains how thesis risk applies to the healthcare space. Thoughts on the company's net income and cash flow in the near future. Reasons to be excited about the next few years in the healthcare space.